GenoImmune, a subsidiary of Shenzhen sequencing company BGI, raised $18 million in an A funding round to support its neoantigen discovery for new immunotherapy candidates. The company has developed a service package to detect neoantigens by combining a neoantigen prediction algorithm with whole paired tumor/normal exome and transcriptome sequencing protocols. The protocols are optimized for difficult FFPE or biopsy samples. BGI, formerly known as the Beijing Genomic Institute, developed the techniques. The A round was led by GF Xinde Investment Management, a PE subsidiary of GF Securities.
Source: China Biotoday